Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    M16-438
Previous Study | Return to List | Next Study

A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03234712
Recruitment Status : Recruiting
First Posted : July 31, 2017
Last Update Posted : November 5, 2019
Sponsor:
Information provided by (Responsible Party):
AbbVie

Brief Summary:
This is an open-label, Phase 1, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of ABBV-321 for participants with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR). The study will consist of 2 phases: Dose Escalation Phase and Expansion Phase.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Cancer Drug: ABBV-321 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)
Actual Study Start Date : October 10, 2017
Estimated Primary Completion Date : March 7, 2024
Estimated Study Completion Date : September 4, 2025

Resource links provided by the National Library of Medicine

Drug Information available for: Urogastrone

Arm Intervention/treatment
Experimental: ABBV-321
ABBV-321 will be administered via intravenous infusion at escalating dose levels until the maximum tolerated dose is reached and a recommended Phase 2 dose is determined.
Drug: ABBV-321
Intravenous infusion




Primary Outcome Measures :
  1. AUCt for ABBV-321 [ Time Frame: Up to 78 days post dose ]
    Area Under the Plasma Concentration-time Curve from Time 0 to the Time of the Last Measurable Concentration (AUCt) for ABBV-321

  2. AUC∞ for ABBV-321 [ Time Frame: Up to 78 days post dose ]
    AUC∞ is the area under the plasma concentration-time curve from Time 0 to infinite time.

  3. Tmax of ABBV-321 [ Time Frame: Up to 78 days post dose ]
    Time to Cmax (Tmax) of ABBV-321

  4. Terminal phase elimination rate constant (β) for ABBV-321 [ Time Frame: Up to 78 days post dose ]
    Terminal phase elimination rate constant (β)

  5. Cmax of ABBV-321 [ Time Frame: Up to 78 days post dose ]
    Maximum observed plasma concentration (Cmax) of ABBV-321

  6. Dose Escalation Phase: Recommended Phase 2 dose (RPTD) for ABBV-321 [ Time Frame: Minimum first cycle of dosing (up to 28 days) ]
    The RPTD will be determined using available safety and pharmacokinetics data upon completion of the Dose Escalation Phase

  7. t1/2 for ABBV-321 [ Time Frame: Up to 78 days post dose ]
    Terminal elimination half-life (t1/2)

  8. Dose Escalation Phase: Maximum tolerated dose (MTD) of ABBV-321 [ Time Frame: Minimum first cycle of dosing (up to 28 days) ]
    The MTD of ABBV-321 will be determined during the dose escalation phase of the study.


Secondary Outcome Measures :
  1. Progression-Free Survival (PFS) [ Time Frame: Up to approximately 5 years ]
    PFS is defined as the number of days from the first dose date to the earliest date of disease progression per RECIST 1.1 or RANO criteria or death, whichever occurred first.

  2. Duration of Response (DOR) [ Time Frame: Up to approximately 5 years ]
    DOR for a given participant is defined as the number of days from the day CR or PR (whichever is recorded first) occurred to the earliest date of disease progression per RECIST 1.1 or RANO criteria or death, whichever occurred first.

  3. Disease Control Rate (DCR) [ Time Frame: Up to 5 years ]
    DCR is defined as the proportion of participants with objective evidence of complete response (CR), partial response (PR) or stable disease (SD); a participants best overall response assignment of SD must be maintained for at least 6 weeks since the first dose date of study drug.

  4. Time to progression (TTP) [ Time Frame: Up to approximately 5 years ]
    TTP is defined as the number of days from the first dose date to the earliest date of disease progression per RECIST version 1.1 or RANO criteria.

  5. Change from Baseline in QTcF [ Time Frame: Up to 61 days post dose ]
    QT interval measurement corrected by Fridericia's formula (QTcF) change from baseline

  6. Overall Survival (OS) [ Time Frame: Up to approximately 5 years ]
    OS is defined as number of days from the date of the first dose to the date of death for all dosed participants. For participants who are not deceased, the data will be censored at the last known date to be alive.

  7. Objective response rate (ORR) [ Time Frame: Up to 5 years ]
    ORR is defined as the proportion of participants with a response of partial response (PR) or better; Response Assessment in Neuro-Oncology (RANO) criteria will be used for glioblastoma (GBM) participants, and Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria will be used for all other participants.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
  • Histologically or cytologically confirmed solid tumor of one of the following types associated with overexpression of Epidermal Growth Factor Receptor (EGFR). (For Expansion Phase: Subjects must have EGFR overexpression demonstrated by central assessment or Sponsor selected test).

Dose Escalation Phase:

  • Colorectal cancer (CRC), Glioblastoma (GBM), squamous cell carcinoma of the head and neck (HNSCC), non-small cell lung cancer (NSCLC), bladder, cervical, esophageal, kidney or sarcoma.
  • Participants must have disease that has progressed on prior treatment and is not amenable to surgical resection or other approved therapeutic options with curative intent. Participants must not be eligible for, or has refused further therapy that is likely to provide a survival benefit.
  • Must have measureable disease as per RECIST Version 1.1 or RANO (for GBM).
  • Minimum life expectancy of at least 12 weeks.

Expansion Phase (Solid Tumor Cohort):

  • Histologically or cytologically confirmed advanced solid tumor.
  • Participants must have disease that has progressed on prior treatment and is not amenable to surgical resection or other approved therapeutic options with curative intent.
  • Must have measureable disease as per RECIST Version 1.1.
  • Minimum life expectancy of at least 12 weeks.

Expansion Phase (GBM Cohort Only):

  • Participant has recurrent primary (de novo) glioblastoma histologically confirmed at any time from initial diagnosis through latest recurrence.
  • Participant has recurrent GBM per Response Evaluation in Neuro-Oncology (RANO) requirements.
  • Tumor is measurable according to RANO criteria.

Exclusion Criteria:

  • Active uncontrolled infection National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE Grade greater than or equal to 3).
  • New York Heart Association (NYHA) Class III or IV heart failure and/or ejection fraction of < 40% as measured by echocardiogram at screening.
  • Unstable angina pectoris or cardiac ventricular arrhythmia.
  • Myocardial infarction or cerebrovascular accident (CVA) within 6 months.
  • Documented history of capillary leak syndrome within 6 months of study enrollment.
  • Grade 2 or higher peripheral edema, ascites, pleural, or pericardial effusion within 4 weeks of study enrollment or any history of recurrent grade 2 or higher effusions requiring ongoing drainage.
  • Active keratitis or current corneal disorder.
  • Laser-assisted in situ keratomileusis (LASIK) procedure within the last 1 year or cataract surgery within the last 3 months.
  • Major surgery (including opening of the abdomen, chest) within 21 days of the first dose of study drug.
  • Uncontrolled metastases from an extracranial solid tumor to the central nervous system (CNS). Participants with brain metastases from an extracranial solid tumor are eligible after definitive therapy provided they are asymptomatic for at least 2 weeks prior to first dose of ABBV-321.
  • No history of medical condition resulting in nephrotic range proteinuria.
  • Participants must not have been treated in anticancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal therapy, biologic therapy or investigational anti-cancer therapy within a period of 21 days or herbal anticancer therapy within 7 days prior to the first dose of study drug.
  • For approved targeted small molecules, a washout period of 5 half-lives is adequate (no washout period required for subjects currently on erlotinib)
  • Participant must not have been in more than three lines of systemic cytotoxic therapy (excluding adjuvant and neoadjuvant therapy)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03234712


Contacts
Layout table for location contacts
Contact: ABBVIE CALL CENTER 847.283.8955 abbvieclinicaltrials@abbvie.com

Locations
Layout table for location information
United States, Arizona
University of Arizona Cancer Center - Tucson /ID# 213220 Not yet recruiting
Tucson, Arizona, United States, 85724
United States, Arkansas
Highlands Oncology Group /ID# 166132 Recruiting
Fayetteville, Arkansas, United States, 72703-4005
United States, California
UCSD Moores Cancer Center - LaJolla /ID# 215366 Not yet recruiting
La Jolla, California, United States, 92093
The Angeles Clinic and Researc /ID# 166133 Recruiting
Los Angeles, California, United States, 90025
United States, Florida
Cancer Specialists of North Florida - Southpoint /ID# 212940 Not yet recruiting
Jacksonville, Florida, United States, 32256
United States, Illinois
Northwestern University Feinberg School of Medicine /ID# 165191 Not yet recruiting
Chicago, Illinois, United States, 60611-2927
University of Chicago /ID# 166064 Recruiting
Chicago, Illinois, United States, 60637
Northshore University Health System-Evanston /ID# 201095 Recruiting
Evanston, Illinois, United States, 60201
Ingalls Memorial Hosp /ID# 214950 Not yet recruiting
Harvey, Illinois, United States, 60426
United States, Massachusetts
Massachusetts General Hospital /ID# 213173 Not yet recruiting
Boston, Massachusetts, United States, 02114
Beth Israel Deaconess Medical Center /ID# 213174 Not yet recruiting
Boston, Massachusetts, United States, 02215-5400
Dana-Farber Cancer Institute /ID# 212920 Not yet recruiting
Boston, Massachusetts, United States, 02215
United States, New York
Columbia Univ Med Ctr /ID# 167184 Recruiting
New York, New York, United States, 10032
United States, North Carolina
Duke University Medical Center /ID# 166135 Recruiting
Durham, North Carolina, United States, 27710-3000
United States, Rhode Island
Lifespan Cancer Institute /ID# 168600 Recruiting
Providence, Rhode Island, United States, 02903-4923
United States, Texas
South Texas Accelerated Research Therapeutics /ID# 166134 Recruiting
San Antonio, Texas, United States, 78229
Australia, New South Wales
Northern Cancer Institute /ID# 166138 Recruiting
St Leonards, New South Wales, Australia, 2065
Australia, Victoria
Austin Hospital /ID# 166137 Recruiting
Heidelberg, Victoria, Australia, 3084
Israel
Sheba Medical Center /ID# 166398 Recruiting
Ramat Gan, Israel, 5262100
Sponsors and Collaborators
AbbVie
Investigators
Layout table for investigator information
Study Director: AbbVie Inc. AbbVie

Layout table for additonal information
Responsible Party: AbbVie
ClinicalTrials.gov Identifier: NCT03234712     History of Changes
Other Study ID Numbers: M16-438
First Posted: July 31, 2017    Key Record Dates
Last Update Posted: November 5, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by AbbVie:
Advanced Solid Tumors
Epidermal Growth Factor Receptor (EGFR)
Squamous cell carcinoma of the head and neck (HNSCC)
non-small cell lung cancer (NSCLC)
Glioblastoma (GBM)
Cancer
overexpression of Epidermal Growth Factor Receptor (EGFR)
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Mitogens
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action